Avery Therapeutics, Inc Announces a Publication in Nature Scientific Reports Outlining Methods of Acquiring Cardiac MRI Endpoints in High Value Pre-Clinical Models of Heart Failure from University of Arizona Study
TUCSON, Ariz., – April 11, 2022 – Avery Therapeutics, Inc. (Avery), a privately held, pre-clinical stage therapeutics company, today announced a publication in the peer-reviewed scientific journal, Nature Scientific Reports, outlining a novel technique in cardiac magnetic resonance imaging (CMR) data acquisition utilizing smart-signal gradient recalled echo (GRE)-based array sequences, entitled, “Free-breathing gradient recalled echo-based CMR in a swine heart failure model,” (Morris, el al. (2022). Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-07611-8). [Read more…]
TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies
April 8th, 2022, Kobe, Japan – TreeFrog Therapeutics, a French-based biotech company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the incorporation of its Japanese subsidiary (KK) TreeFrog Therapeutics Japan and the establishment of a lab in Kobe, at the Creative Lab for Innovation Kobe (CLIK). [Read more…]
The USPTO Issues a Patent to Cellular Engineering Technologies For Producing Safer Induced Pluripotent Stem Cells
March 24, 2022, Coralville, Iowa — Cellular Engineering Technologies (CET), Inc., an Iowa biotechnology company specializing in cell manufacturing and contract research services, today announced that it has received a patent from the United States Patent and Trademark Office for its virus-free and oncogene-free induced pluripotent stem cell (iPSC) technology. The iPSC technology which was previously published in Future Science Open Access and Regenerative Medicine was developed in collaboration with the John Paul II Medical Research Institute (JP2MRI), a non-profit organization. More recently, the National Institutes of Health awarded CET a SBIR grant to commercialize the technology to provide reproducible iPSC and differentiated neural stem cells that maintain pluripotency and genetic stability during large scale production. [Read more…]
I Peace triples GMP cell manufacturing by expanding CDMO facility
March 7, 2022, Palo Alto, California — I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up, announced that the company had tripled its capacity to manufacture GMP grade iPS cells and iPSC-derived differentiated cells by expanding its facility. The facility’s expansion, designed to conform to GMP standard, is now almost complete and is expected to start manufacturing cGMP grade cells in April this year after going through a regulatory review and FDA registration update. With this CDMO facility expansion, I Peace will be able to meet the growing needs for GMP iPS cells from pharmaceutical companies and cell therapy developers, and better serve individuals with increased personal iPS cell banking service capacity. [Read more…]
